Abstract
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
Cite
CITATION STYLE
APA
Mukherji, S. K. (2010, February). Bevacizumab (avastin). American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.A1987
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free